BioWorld MedTech

Nov. 16, 2015

Mindray merger a precursor to U.S. stock exchange delisting, return to private status

HONG KONG — One of the biggest Chinese medical device companies is undergoing a $3 billion delisting from the U.S. market as it paves the way to head back to its home market and the possibility of more access to investment. Read More

CT colongraphy is again gaining traction on Hill

Mimedx says market overreacted to FDA's recent HCT/P guidance

Colombia defining technological device evaluation guidelines

M&A activity increases as industry gets personal

AHA, Google Life Sciences enter $50M research collaboration

Products

Thermo Fisher authorizes $1 billion share repurchase

Keeping you up to date on recent developments in Neurology

Today's news in brief

BioWorld

BioWorld briefs for May 22, 2026.

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

News in brief

BioWorld Asia

BioWorld Asia briefs for May 19, 2026

Nxera Pharma prepares and tests new GPR17 antagonists

BioWorld Science

Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...

Genescience presents STAT6 degrader for atopic dermatitis

BioWorld Science

Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....